Clinical trials: Chondrosarcoma
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Chondrosarcoma, Metastatic Chondrosarcoma
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
The purpose of this study is to determine the effectiveness and safety of single agent pazopanib in subjects with chondrosarcoma.
- Trial name
- NCT01330966
- Testing
- pazopanib
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 47 people
- Sponsor
- Emerald Clinical Inc.
Isocitrate Dehydrogenase Gene Mutation
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in advanced or metastatic solid tumors with IDH mutation.
- Trial name
- NCT04762602
- Testing
- HMPL-306
- Where
- 11 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Hutchmed
Synovial Sarcoma, Soft Tissue Sarcoma
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
This is an open-label, non-randomized, first-in-human Phase 1/2 study designed to evaluate the safety and tolerability of CFT8634 in subjects with synovial sarcoma and SMARCB1-null tumors who: have received prior systemic…
- Trial name
- NCT05355753
- Testing
- CFT8634
- Where
- 12 sites in United States
- Volunteers
- 49 people
- Sponsor
- C4 Therapeutics, Inc.
Chondrosarcoma
Understanding Engagement Trends in Chondrosarcoma Clinical Trials
Taking part in medical research usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.
- Trial name
- NCT06029478
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Patients with a diagnosis listed under "conditions" below are eligible to be considered for the EAP. These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory…
- Conditions
- Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma, Sinonasal Carcinoma, Small Cell Carcinoma of the Ovary Hypercalcemic Type
- Trial name
- NCT03874455
- Testing
- Tazemetostat
- Sponsor
- Epizyme, Inc.
Solid Tumor, Colorectal Cancer
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of aplitabart as a single agent and in combination in participants with relapsed and/or…
- Conditions
- Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma
- Trial name
- NCT04553692
- Testing
- Aplitabart (IGM-8444), FOLFIRI, Bevacizumab (and approved biosimilars)
- Where
- 58 sites in United States, Australia and 3 more
- Volunteers
- 272 people
- Sponsor
- IGM Biosciences, Inc.